Zemach Sasson, Zohar Joseph
The Jerusalem Mental Health Center, Israel; The Hebrew University in Jerusalem, Israel.
Department of Psychiatry, Sheba Medical Center, Tel-Hashomer, Israel; Sackler School of Medicine, Tel Aviv University, Israel.
Asian J Psychiatr. 2025 Jan;103:104317. doi: 10.1016/j.ajp.2024.104317. Epub 2024 Dec 11.
Neuroscience-based Nomenclature (NbN) is a pharmacologically-driven classification of psychotropics, aiming to revise the current indication-based classification (antipsychotics, antidepressants, anxiolytics etc.). Whereas the number of psychotropics has risen dramatically over the years, the current nomenclature preserves a rather narrow categorization that overlooks the rich neurobiological knowledge accumulated to date. The current classification is confusing for the patients ("Why am I getting an 'antipsychotic' for my depression, Doctor? am I psychotic?"), and consequently interfering with optimal care. To address this issue, leading organizations in psychopharmacology have collaborated to introduce a classification which is based on pharmacological domains (neurotransmitters) and mode of action. This approach may relieve patients from confusing labels and help clinicians plan the next pharmacological step from a neuroscientific prism. NbN has earned endorsements from significant psychiatric bodies (including the American Psychiatric Association and the European Psychiatric Association) and has been incorporated into highly ranked peer-reviewed journals, textbooks, and educational programs. It is accessible through a free app, offering an easy-to-navigate database for professionals, as well as specialized versions for child and adolescent psychiatry and for patient and family education. By bridging the gap between complex neurobiological research and clinical practice, NbN may enhance evidence-based prescription practice and serve as an educational resource. Despite its inherent challenges, this initiative may represent a step towards integrating neuroscience into everyday psychiatric care, making it more understandable and relevant for all involved.
基于神经科学的命名法（NbN）是一种由药理学驱动的精神药物分类方法，旨在修订当前基于适应症的分类法（抗精神病药、抗抑郁药、抗焦虑药等）。尽管多年来精神药物的数量急剧增加，但当前的命名法仍保留着相当狭窄的分类，忽视了迄今为止积累的丰富神经生物学知识。当前的分类法让患者感到困惑（“医生，为什么我治疗抑郁症要用‘抗精神病药’？我是精神病患者吗？”），从而干扰了最佳治疗。为了解决这个问题，精神药理学领域的主要组织合作推出了一种基于药理学领域（神经递质）和作用方式的分类法。这种方法可能会让患者摆脱令人困惑的标签，并帮助临床医生从神经科学的角度规划下一步的药物治疗步骤。NbN已获得重要精神病学机构（包括美国精神病学协会和欧洲精神病学协会）的认可，并已被纳入高排名的同行评审期刊、教科书和教育项目中。它可以通过一个免费应用程序访问，为专业人员提供一个易于导航的数据库，以及针对儿童和青少年精神病学以及患者和家庭教育的专门版本。通过弥合复杂的神经生物学研究与临床实践之间的差距，NbN可能会加强循证处方实践，并作为一种教育资源。尽管存在固有的挑战，但这一举措可能代表着朝着将神经科学融入日常精神病护理迈出的一步，使其对所有相关人员来说更易于理解和相关。
